Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma
Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma
INTRODUCTION: The National Institute for Health and Clinical Excellence (NICE) has previously recommended pemetrexed plus cisplatin for the treatment of patients with advanced malignant pleural mesothelioma (MPM) and WHO performance status 0-1. Subsequent to this appraisal, randomised controlled trial (RCT) data for raltitrexed plus cisplatin and comparing chemotherapy to active symptom control (ASC) has become available, allowing a more complete analysis of the comparative efficacy and cost-effectiveness of first-line chemotherapy in MPM.
METHODS: An adjusted indirect comparison is used to estimate the relative efficacy of raltitrexed plus cisplatin and pemetrexed plus cisplatin. A cost-effectiveness model is used to assess the lifetime costs and health outcomes associated with these comparators and ASC. Patient level data from the EORTC 08983 trial are used to estimate baseline progression and survival rates. Relative treatment effects are taken from RCTs; cost and utility data from the literature.
RESULTS: Raltitrexed plus cisplatin and pemetrexed plus cisplatin were not found to be statistically significantly different with respect to overall response, progression free survival or overall survival. The cost-effectiveness analysis found raltitrexed plus cisplatin to be cost-effective at a cost per quality adjusted life year of £13,454 compared to cisplatin and £27,360 compared to ASC. Pemetrexed plus cisplatin is dominated by raltitrexed plus cisplatin as the raltitrexed combination offers marginally higher quality adjusted life years (QALYs) and life years (LYs) at a substantially lower total cost.
CONCLUSION: Raltitrexed plus cisplatin is a cost-effective first-line treatment for MPM. This conclusion was maintained across a number of sensitivity analyses.
Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Cisplatin/administration & dosage, Cost-Benefit Analysis, Glutamates/administration & dosage, Guanine/administration & dosage, Health Care Costs, Humans, Mesothelioma/drug therapy, Pemetrexed, Pleural Neoplasms/drug therapy, Quality-Adjusted Life Years, Quinazolines/administration & dosage, Randomized Controlled Trials as Topic, Thiophenes/administration & dosage
261-267
Woods, Beth
5cc14644-2bc4-4eb0-bc67-a3f18d2db809
Paracha, Noman
7e6db99f-1943-4121-b74d-110f82ec843b
Scott, David A
19b5fd34-9974-4ae4-8be0-27a693639e20
Thatcher, Nicholas
8d83757f-e099-410e-9290-4917cbd7cd35
February 2012
Woods, Beth
5cc14644-2bc4-4eb0-bc67-a3f18d2db809
Paracha, Noman
7e6db99f-1943-4121-b74d-110f82ec843b
Scott, David A
19b5fd34-9974-4ae4-8be0-27a693639e20
Thatcher, Nicholas
8d83757f-e099-410e-9290-4917cbd7cd35
Woods, Beth, Paracha, Noman, Scott, David A and Thatcher, Nicholas
(2012)
Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma.
Lung Cancer, 75 (2), .
(doi:10.1016/j.lungcan.2011.07.011).
Abstract
INTRODUCTION: The National Institute for Health and Clinical Excellence (NICE) has previously recommended pemetrexed plus cisplatin for the treatment of patients with advanced malignant pleural mesothelioma (MPM) and WHO performance status 0-1. Subsequent to this appraisal, randomised controlled trial (RCT) data for raltitrexed plus cisplatin and comparing chemotherapy to active symptom control (ASC) has become available, allowing a more complete analysis of the comparative efficacy and cost-effectiveness of first-line chemotherapy in MPM.
METHODS: An adjusted indirect comparison is used to estimate the relative efficacy of raltitrexed plus cisplatin and pemetrexed plus cisplatin. A cost-effectiveness model is used to assess the lifetime costs and health outcomes associated with these comparators and ASC. Patient level data from the EORTC 08983 trial are used to estimate baseline progression and survival rates. Relative treatment effects are taken from RCTs; cost and utility data from the literature.
RESULTS: Raltitrexed plus cisplatin and pemetrexed plus cisplatin were not found to be statistically significantly different with respect to overall response, progression free survival or overall survival. The cost-effectiveness analysis found raltitrexed plus cisplatin to be cost-effective at a cost per quality adjusted life year of £13,454 compared to cisplatin and £27,360 compared to ASC. Pemetrexed plus cisplatin is dominated by raltitrexed plus cisplatin as the raltitrexed combination offers marginally higher quality adjusted life years (QALYs) and life years (LYs) at a substantially lower total cost.
CONCLUSION: Raltitrexed plus cisplatin is a cost-effective first-line treatment for MPM. This conclusion was maintained across a number of sensitivity analyses.
This record has no associated files available for download.
More information
e-pub ahead of print date: 19 September 2011
Published date: February 2012
Keywords:
Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Cisplatin/administration & dosage, Cost-Benefit Analysis, Glutamates/administration & dosage, Guanine/administration & dosage, Health Care Costs, Humans, Mesothelioma/drug therapy, Pemetrexed, Pleural Neoplasms/drug therapy, Quality-Adjusted Life Years, Quinazolines/administration & dosage, Randomized Controlled Trials as Topic, Thiophenes/administration & dosage
Identifiers
Local EPrints ID: 441410
URI: http://eprints.soton.ac.uk/id/eprint/441410
ISSN: 0169-5002
PURE UUID: 7e5e1df3-1268-496e-8d0c-f6a3632d2d27
Catalogue record
Date deposited: 11 Jun 2020 16:39
Last modified: 17 Mar 2024 04:02
Export record
Altmetrics
Contributors
Author:
Beth Woods
Author:
Noman Paracha
Author:
David A Scott
Author:
Nicholas Thatcher
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics